IPHA INNATE PHARMA S A

Ownership history in MORGAN STANLEY  ·  24 quarters on record

This page tracks every 13F SEC filing in which MORGAN STANLEY reported a position in INNATE PHARMA S A (IPHA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 46,394 -7,170 -13.4% 0.00% $81K $1.75
2025 Q3 ADDED 53,564 +2,340 +4.6% 0.00% $103K $1.93
2025 Q2 ADDED 51,224 +7,700 +17.7% 0.00% $93K $1.82
2025 Q1 UNCHANGED 43,524 0% 0.00% $77K $1.78
2024 Q4 UNCHANGED 43,524 0% 0.00% $80K $1.84
2024 Q3 UNCHANGED 43,524 0% 0.00% $100K $2.29
2024 Q2 REDUCED 43,524 -600 -1.4% 0.00% $84K $1.94
2024 Q1 REDUCED 44,124 -2,230 -4.8% 0.00% $127K $2.88
2023 Q4 ADDED 46,354 +1,400 +3.1% 0.00% $130K $2.80
2023 Q3 REDUCED 44,954 -2,095 -4.5% 0.00% $114K $2.53
14 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    IPHA price (monthly, adj. close)
← Back to MORGAN STANLEY Holdings